Culture Biosciences · Jul 2026
Describes a MilliporeSigma case study using Nexxys to execute five full-factorial DOE studies across CHOZN cell lines and confirm optimized conditions at 3 L bench scale.
We grow cells for biotech companies.
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Culture Biosciences builds cloud-connected bioreactors and the Console platform for remotely designing, running, monitoring, and analyzing upstream bioprocess and cell-culture experiments; it also offers managed bioprocess development services under Nexxys and Stratyx bioreactor hardware.
Primary product
Console, the cloud-based bioprocess management software platform
Founded
2016
Headquarters
South San Francisco, California, United States
Team size
51-200
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
Upstream bioprocess development / cloud biomanufacturing infrastructure
Offices
3 jobs at Culture Biosciences
Business model
Stage
Series C
Total raised
$101.7M
Latest round
Series C · Dec 2025
Dec 2025 · Northpond Ventures, Synthesis Capital, S32, and Cultivian Sandbox
Oct 2021 · Northpond Ventures
Mar 2020 · Cultivian Sandbox Ventures
Sep 2019 · America’s Seed Fund
Feb 2019 · Section 32
Leadership
Chief Executive Officer
Scott Greenstone
Senior Vice President, Finance
Lauren Kellogg
Vice President of Strategy & Corporate Development
Director, Human Resources
Senior Director Engineering
Vice President Operations
Director, Commercial Software Product & IT
Culture presents itself as a collaborative, innovation-driven team focused on making bioprocess development easier and faster; public career pages emphasize teamwork, customer-centricity, and informal team-building.
Work style
Flexible
Compensation
No public salary bands were found. Public employer-rating data on LinkedIn shows compensation at 2.7/5.0, suggesting mixed sentiment rather than a published pay scale.
Benefits
Pricing
Custom quote / statement-of-work pricing for managed bioprocess services; no public list pricing was found.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M (LinkedIn estimate; around $9.8M reported in company profile data)
Culture Biosciences · Jul 2026
Describes a MilliporeSigma case study using Nexxys to execute five full-factorial DOE studies across CHOZN cell lines and confirm optimized conditions at 3 L bench scale.
Culture Biosciences · Dec 2025
Announced a Series C led by existing investors including Northpond Ventures, Synthesis Capital, S32, and Cultivian Sandbox; proceeds support Stratyx 250 commercialization and Console AI/software expansion.
Culture Biosciences · Dec 2025
Announced a collaboration to bring Culture’s AI and machine-learning tools into Xcellbio’s AVATAR Foundry system for cell therapy development and manufacturing analytics.
Culture Biosciences · Apr 2025
Introduced Stratyx 250, positioning it as the next generation cloud-integrated mobile bioreactor for process development.
Culture Biosciences · Sep 2024
Announced a strategic collaboration to integrate Console with Google Cloud tools such as Gemini AI, BigQuery, and Looker for faster bioprocess development and analytics.